Study guide
2.2 Uterotonic Pharmacology & Stepwise Administration Protocols
C-OBE Obstetric Emergencies Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Maternal Assessment, Risk Stratification & Early Warning Systems
1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification 1.2 Dynamic Antepartum & Intrapartum Risk Assessment 1.3 Maternal Early Warning Systems (MEWS/MEWT) & Critical Triage Physical Assessment 1.4 Alliance for Innovation on Maternal Health (AIM) Safety Bundles & Emergency Readiness
2 Chapter 2: Obstetric Hemorrhage — Etiology, Assessment & Uterotonics
2.1 Postpartum Hemorrhage Etiology (4 T's) & Quantitative Blood Loss (QBL) 2.2 Uterotonic Pharmacology & Stepwise Administration Protocols 2.3 Tranexamic Acid (TXA) Protocols & Hemorrhage Timing
3 Chapter 3: Obstetric Hemorrhage — Mechanical Interventions, Placental Disorders & Transfusion
3.1 Intrauterine Tamponade Balloons, Compression Sutures & Surgical Hemostasis 3.2 Ectopic Pregnancy, Placenta Previa, Accreta Spectrum (PAS), Abruption & Vasa Previa 3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)
4 Chapter 4: Hypertensive Disorders of Pregnancy & Preeclampsia with Severe Features
4.1 Classification & Spectrum of Hypertensive Disorders of Pregnancy 4.2 Preeclampsia with Severe Features: Pathophysiology & End-Organ Damage 4.3 Diagnostic Evaluation, Laboratory Triggers & Fetal Surveillance in Preeclampsia
5 Chapter 5: Hypertensive Crisis, Eclampsia & Magnesium Sulfate Therapy
5.1 Acute Severe Hypertension & First-Line Antihypertensive Protocols 5.2 Eclampsia Recognition, Seizure Management & Airway Protection 5.3 Magnesium Sulfate Neuroprotection/Seizure Prophylaxis Protocols, Monitoring & Toxicity Reversal 5.4 HELLP Syndrome & Hepatic Crisis Management
6 Chapter 6: Maternal Resuscitation, Cardiac Arrest & Perimortem Cesarean
6.1 Maternal ACLS Modifications & Cardiopulmonary Resuscitation Physiology 6.2 Etiologies of Maternal Arrest & Structured Emergency Response 6.3 Perimortem Cesarean Delivery (PMCD / Resuscitative Hysterotomy)
7 Chapter 7: Amniotic Fluid Embolism & Maternal Shock States
7.1 Amniotic Fluid Embolism (AFE): Pathophysiology & Clinical Presentation 7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE 7.3 Maternal Shock States: Hemorrhagic, Distributive, Cardiogenic & Obstructive
8 Chapter 8: Acute Intrapartum Delivery Emergencies
8.1 Shoulder Dystocia: Recognition, Timing & Primary HELPERR Sequence 8.2 Advanced Shoulder Dystocia Maneuvers & Neonatal Brachial Plexus Injury Prevention 8.3 Umbilical Cord Prolapse Recognition & Emergent Decompression Protocols
9 Chapter 9: Uterine Inversion, Malpresentation & Obstetric Trauma
9.1 Acute Uterine Inversion: Recognition, Tocolysis & Manual/Surgical Reduction 9.2 Emergency Vaginal Breech Extraction & Head Entrapment Maneuvers 9.3 Maternal Trauma: Primary/Secondary Survey, Placental Abruption & Fetomaternal Hemorrhage
10 Chapter 10: Maternal Sepsis, Intraamniotic Infection & Severe Infections
10.1 Maternal Sepsis: Physiological Criteria, S.O.S. Score & omSOFA 10.2 The Maternal Sepsis Hour-1 Bundle & Fluid/Vasopressor Optimization 10.3 Intraamniotic Infection (Triple I / Chorioamnionitis) & Severe Endometritis 10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections
11 Chapter 11: Endocrine, Cardiovascular, Respiratory & Neurologic Emergencies
11.1 Diabetic Ketoacidosis (DKA), Maternal Hypoglycemia & Endocrine Resuscitation in Pregnancy 11.2 Peripartum Cardiomyopathy (PPCM), Acute Heart Failure, Acute Coronary Syndromes & Maternal Arrhythmias 11.3 Status Asthmaticus, Pulmonary Edema & ARDS in Pregnancy 11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)
12 Chapter 12: Thromboembolism, Hepatorenal Disorders & Toxicologic Emergencies
12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation 12.2 Acute Fatty Liver of Pregnancy (AFLP / Swansea Criteria) & Acute Kidney Injury 12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration
13 Chapter 13: Obstetric Anesthesia Emergencies & Critical Complications
13.1 High Spinal / Total Spinal Anesthesia & Aspiration Pneumonitis 13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol 13.3 Post-Dural Puncture Headache (PDPH), Epidural Hematoma & Abscess 13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol
14 Chapter 14: Professional Practice, Team Communication, Debriefing & Health Equity
14.1 Crisis Resource Management (CRM), TeamSTEPPS & Structured Communication 14.2 Multidisciplinary Emergency Debriefing, Morbidity & Mortality, and Systems Learning 14.3 Perinatal Racial/Ethnic Disparities, Implicit Bias Mitigation & Respectful Maternity Care 14.4 Legal, Ethical, Documentation & EMTALA Standards in Obstetric Emergencies
2.2 Uterotonic Pharmacology & Stepwise Administration Protocols
Key Takeaways Explain This Topic AI
Oxytocin is the universal first-line agent for both postpartum hemorrhage prophylaxis (10 units IM or 10–40 units/L IV infusion) and treatment of uterine atony; it must NEVER be administered as an undiluted rapid IV bolus due to risk of fatal cardiovascular collapse and severe hypotension.
Methylergonovine (Methergine, 0.2 mg IM) is an ergot alkaloid that produces sustained tetanic uterine contractions but is strictly contraindicated in patients with gestational hypertension, preeclampsia, chronic hypertension, or coronary artery disease.
Carboprost tromethamine (Hemabate, 250 mcg IM/intramyometrial) is a prostaglandin F2α analog that is highly effective for atony but absolutely contraindicated in patients with active asthma or severe reactive airway disease due to potent bronchoconstrictive properties.
Misoprostol (Cytotec, 800–1,000 mcg PR or 600–800 mcg SL/PO) is a synthetic prostaglandin E1 analog that is safe in both hypertensive and asthmatic patients, with sublingual administration offering the fastest onset (peak 30 min) and rectal administration providing the longest duration of action (4 hours).
Stepwise uterotonic escalation requires immediate matching of secondary pharmacologic agents to patient-specific co-morbidities to prevent life-threatening contraindication errors while mobilizing mechanical tamponade systems.
Last updated: August 2026
2.2 Uterotonic Pharmacology & Stepwise Administration Protocols
Uterine atony accounts for approximately 80% of all postpartum hemorrhage cases. Rapid, decisive pharmacologic management aimed at restoring myometrial tone is the cornerstone of secondary prevention and primary treatment. Because maternal hemodynamic collapse can develop within minutes of delivery, clinicians must possess an intimate mastery of the receptor pharmacodynamics , exact dosing regimens , routes of administration , adverse effect profiles , and absolute contraindications of every first- and second-line uterotonic agent.
1. Myometrial Contractility & Pharmacologic Principles
Myometrial contraction is governed by the intracellular concentration of free ionized calcium ( C a 2 + Ca^{2+} C a 2 + ). When uterotonic agents bind their respective G-protein coupled receptors on myometrial cell membranes, they stimulate phospholipase C (PLC), producing inositol trisphosphate ( I P 3 IP_3 I P 3 ) and diacylglycerol (DAG). I P 3 IP_3 I P 3 triggers the rapid release of C a 2 + Ca^{2+} C a 2 + from the sarcoplasmic reticulum into the cytoplasm. Free calcium binds calmodulin, activating myosin light-chain kinase (MLCK) , which phosphorylates myosin heads and induces cross-bridge cycling with actin filaments, generating mechanical smooth muscle contraction.
Receptor Desensitization and Oxytocin Tolerance
During prolonged labors characterized by high-dose, protracted intrapartum oxytocin augmentation, myometrial oxytocin receptors undergo extensive homologous desensitization , internalization, and downregulation. Consequently, when postpartum uterine atony develops in an oxytocin-pretreated patient, simply increasing the oxytocin infusion rate often yields diminishing clinical returns. Clinicians must recognize this pharmacodynamic tolerance early and rapidly escalate to alternative uterotonic drug classes that target non-oxytocin receptor pathways (e.g., ergot alkaloids and prostanoid receptors).
2. Comprehensive Uterotonic Drug Profiles
Drug Name & Class Standard Dosage & Route Onset & Duration Receptor & Mechanism Absolute Contraindications Common Adverse Effects & Clinical Warnings
Oxytocin (Pitocin) ; Synthetic Nonapeptide Prophylaxis: 10 U IM or 10–40 U in 500–1,000 mL IV crystalloid.; Treatment: 10–40 U in 1,000 mL IV at 250–500 mL/hr (or 10 U IM). IV: <1 min onset; duration 20–60 min.; IM: 3–5 min onset; duration 2–3 hours. Oxytocin receptors ( G q G_q G q ); stimulates I P 3 IP_3 I P 3 /calcium influx; produces rhythmic coordinated contractions. Hypersensitivity (none in acute life-threatening atony). BLACK-BOX WARNING: NEVER give rapid undiluted IV bolus (causes severe peripheral vasodilation, profound hypotension, coronary vasospasm, arrhythmia, collapse). Free water intoxication / hyponatremia with prolonged high-volume infusions (ADH homology).
Methylergonovine (Methergine) ; Ergot Alkaloid 0.2 mg IM (or intrauterine / intramyometrial).; May repeat q2–4h (max 5 doses / 1.0 mg). IM: 2–5 min onset; duration 3 hours.; PO: 5–10 min; duration 3 hours. Partial agonist at α-adrenergic, 5- H T 2 HT_2 H T 2 , and dopaminergic receptors; produces sustained tetanic contraction. HYPERTENSION , Pre-eclampsia, Eclampsia, Gestational HTN, Coronary artery disease, Raynaud's phenomenon. Sudden severe hypertensive crisis, cerebrovascular accident (stroke), myocardial ischemia, nausea, vomiting, severe headache. Avoid IV push (causes catastrophic intracranial hemorrhage). Requires refrigeration (2–8°C) and light protection.
Carboprost Tromethamine (Hemabate / 15-methyl PGF2α) ; Prostaglandin F2α 250 mcg (0.25 mg) IM or deep intramyometrial.; May repeat q15–90 min (max 8 doses / 2.0 mg). IM: 15–30 min onset; duration 4–6 hours. Prostaglandin F ( F P FP FP ) receptors; stimulates intracellular calcium; potent myometrial and vascular smooth muscle constriction. ACTIVE ASTHMA , Severe reactive airway disease, Acute pulmonary disease. Severe bronchospasm, acute airway resistance, profound watery diarrhea (60–80%), nausea, vomiting, drug-induced pyrexia / hyperthermia (up to 103–104°F / 39–40°C), transient hypertension. Co-prescribe loperamide and antiemetics. Requires refrigeration.
Misoprostol (Cytotec) ; Prostaglandin E1 Analog 800 – 1,000 mcg PR (rectal); OR 600 – 800 mcg SL (sublingual); OR 600 – 800 mcg PO (oral). SL: 8–10 min onset, peak 30 min.; PR: 20 min onset, peak 60 min, duration up to 4 hours. Prostaglandin E ( E P 2 / E P 3 EP_2/EP_3 E P 2 / E P 3 ) receptors; mobilizes calcium; produces sustained myometrial tone. Hypersensitivity to prostaglandins. Intense shivering / rigors (up to 50%), transient high fever (pyrexia up to 40°C), abdominal cramping, diarrhea, nausea. Key Advantage: Safe in BOTH hypertension and asthma; thermostable at room temperature (no cold chain required).
- In-Depth Clinical Pharmacology Breakdown
- 1. Oxytocin (Pitocin)
Receptor Kinetics & Administration: Oxytocin acts on G-protein coupled oxytocin receptors located on the cell membranes of myometrial smooth muscle. In the third stage of labor, routine prophylactic administration immediately following delivery of the anterior shoulder or neonate reduces the incidence of PPH by nearly 50%.
The Danger of IV Bolus Injection: Undiluted rapid IV push of oxytocin produces direct relaxation of vascular smooth muscle, causing profound peripheral vasodilation, systemic vascular resistance collapse, precipitous hypotension, reflex tachycardia, and myocardial ischemia. It must ALWAYS be administered as a dilute continuous intravenous infusion (e.g., 20–40 units in 1,000 mL normal saline or lactated Ringer's) or as an intramuscular injection (10 units IM).
Water Intoxication (Hyponatremic Encephalopathy): Oxytocin shares 8 of its 9 amino acid residues with arginine vasopressin (antidiuretic hormone / ADH). Prolonged, high-volume infusion of oxytocin in hypotonic crystalloid fluids (such as 5% Dextrose in water) exerts an intense antidiuretic effect on renal collecting tubules, causing free water retention, severe hyponatremia, cerebral edema, maternal seizures, coma, and death.
2. Methylergonovine Maleate (Methergine)
Mechanism of Action: Methylergonovine is a semi-synthetic ergot alkaloid that acts as a potent agonist on smooth muscle alpha-1-adrenergic and serotonin 5- H T 2 HT_2 H T 2 receptors. Unlike oxytocin, which produces rhythmic, peristaltic contractions, methylergonovine produces a sustained, non-relaxing, tetanic uterine contraction , which provides intense mechanical compression of myometrial blood vessels.
The Hypertensive Hazard: Because alpha-adrenergic receptors are heavily distributed throughout the systemic arterial vasculature, methylergonovine induces intense peripheral vasoconstriction. In patients with pre-existing endothelial dysfunction or elevated vascular resistance (such as preeclampsia, gestational hypertension, or chronic hypertension), Methergine can trigger acute hypertensive crisis, intracranial hemorrhage (hemorrhagic stroke), retinal detachment, or acute coronary artery spasm with myocardial infarction.
3. Carboprost Tromethamine (Hemabate / 15-Methyl Prostaglandin F2α)
Mechanism of Action: Carboprost is a synthetic 15-methyl analog of naturally occurring prostaglandin F2α (PGF2α). The 15-methyl substitution prevents rapid metabolic oxidation and inactivation by 15-hydroxyprostaglandin dehydrogenase, yielding a prolonged biological half-life and potent myometrial stimulation.
The Bronchospasm Hazard: PGF2α receptors are heavily expressed in bronchial smooth muscle. Activation of these receptors induces intense bronchoconstriction and increased pulmonary airway resistance . In asthmatic patients or those with reactive airway disease, carboprost can precipitate intractable, life-threatening status asthmaticus, severe ventilation-perfusion mismatch, and hypoxemic respiratory arrest.
Thermoregulatory & Gastrointestinal Effects: Carboprost stimulates smooth muscle throughout the gastrointestinal tract, causing explosive secretory diarrhea, nausea, and vomiting in up to 80% of patients. Additionally, carboprost crosses the blood-brain barrier to act on hypothalamic thermoregulatory centers, frequently causing a transient drug-induced hyperthermia (temperature spikes up to 39–40°C / 102–104°F) within 1 to 2 hours of administration. Clinicians must distinguish this benign, self-limiting drug fever from intraamniotic infection / septic shock.
4. Misoprostol (Cytotec / Prostaglandin E1)
Mechanism & Route Nuances: Misoprostol is a synthetic prostaglandin E1 ( P G E 1 PGE_1 PG E 1 ) methyl ester analog. It is completely stable at ambient room temperature, making it a critical agent in low-resource settings and pre-hospital environments where refrigeration is unavailable.
Pharmacokinetics by Route:
Sublingual (SL): Demonstrates the highest peak plasma concentration ( C m a x C_{max} C ma x ) and fastest onset (8–10 minutes, peak at 30 minutes) due to direct absorption into the internal jugular venous drainage, bypassing first-pass hepatic metabolism.
Rectal (PR): Demonstrates a slower onset (peak 60 minutes) but provides a prolonged, sustained plateau phase lasting up to 4 hours. Rectal delivery (800–1,000 mcg PR) is the route of choice when the patient is vomiting, sedated under general anesthesia, or undergoing open abdominal surgery.
Shivering & Pyrexia: High-dose misoprostol frequently triggers intense, dramatic shivering (rigors) in up to 50% of parturients, accompanied by transient high-grade pyrexia. Patients and families should be reassured that this is a benign pharmacologic side effect, which can be managed with warm blankets and antipyretics.
3. Stepwise Algorithmic Escalation & Co-Morbidity Matrix
When uterine atony is refractory to first-line oxytocin infusion, second-line uterotonics must be selected deliberately based on the patient's individual clinical profile and medical co-morbidities. +-----------------------------------------------------------------------------+
- | UTEROTONIC CO-MORBIDITY DECISION MATRIX |
- | |
- | [PATIENT CLINICAL PROFILE] [PREFERRED AGENT] [STRICTLY AVOID] |
- | |
- | 1. Normotensive, Non-Asthmatic ---> Methergine ---> None |
- | (or Hemabate) |
- | |
- | 2. Hypertensive / Preeclamptic ---> Hemabate ---> METHERGINE |
- | (or Misoprostol) |
- | |
- | 3. Active Asthma / Wheezing ---> Methergine ---> HEMABATE |
- | (or Misoprostol) |
- | |
- | 4. BOTH Asthma AND Preeclampsia ---> MISOPROSTOL ---> METHERGINE |
- | (+ Tamponade) AND HEMABATE |
- +-----------------------------------------------------------------------------+
- 4. Mechanical Tamponade Systems & Pharmacologic Synergy
When pharmacotherapy fails to achieve sustained myometrial tone, mechanical uterine tamponade systems must be deployed without delay while medical resuscitation continues. +-----------------------------------------------------------------------------+
- | MECHANICAL UTERINE TAMPONADE MODALITIES |
- | |
- | 1. INTRAUTERINE BALLOON TAMPONADE (Bakri Balloon) |
- | - Silicone balloon inserted into uterine cavity. |
- | - Instilled with 300 to 500 mL of sterile warm saline. |
- | - Exerts inward-to-outward radial pressure against bleeding sinuses. |
- | - Tamponade Test: Cessation of dark bleeding from drainage port |
- | indicates success; persistent brisk bleeding mandates surgical OR. |
- | - Maintained on continuous low-dose oxytocin (to prevent expulsion) |
- | and prophylactic antibiotics for 12 to 24 hours. |
- | |
- | 2. VACUUM-INDUCED UTERINE TAMPONADE (JADA System) |
- | - Intrauterine silicone loop connected to low continuous wall suction |
- | (-80 mmHg ± 10 mmHg). |
- | - Evacuates blood/clots and generates negative intrauterine pressure. |
- | - Mechanically collapses the endometrial cavity and induces natural |
- | physiological myometrial contraction and spiral artery occlusion. |
- | - Rapid median time to bleeding control (<5 minutes in responders). |
- +-----------------------------------------------------------------------------+